These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31429099)

  • 1. Maintenance therapy in AML: The past, the present and the future.
    Molica M; Breccia M; Foa R; Jabbour E; Kadia TM
    Am J Hematol; 2019 Nov; 94(11):1254-1265. PubMed ID: 31429099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting maintenance therapy in acute myeloid leukemia with novel agents.
    Canaani J; Luger SM
    Curr Opin Hematol; 2016 Mar; 23(2):175-80. PubMed ID: 26766539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Lee CJ; Shiraz P; Muffly L
    Leuk Lymphoma; 2017 Mar; 58(3):516-527. PubMed ID: 27685315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML and the art of remission maintenance.
    de Lima M; Roboz GJ; Platzbecker U; Craddock C; Ossenkoppele G
    Blood Rev; 2021 Sep; 49():100829. PubMed ID: 33832807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia.
    Patel SA; Litzow MR; Cerny J
    Blood Rev; 2021 Nov; 50():100863. PubMed ID: 34210571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy in acute myeloid leukemia: What is the future?
    McMahon CM; Luger SM
    Semin Hematol; 2019 Apr; 56(2):102-109. PubMed ID: 30926085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
    Baer MR; George SL; Caligiuri MA; Sanford BL; Bothun SM; Mrózek K; Kolitz JE; Powell BL; Moore JO; Stone RM; Anastasi J; Bloomfield CD; Larson RA
    J Clin Oncol; 2008 Oct; 26(30):4934-9. PubMed ID: 18591543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
    Al-Shaibani E; Novitzky-Basso I; Mattsson J; Kim DDH
    Int J Hematol; 2023 Jul; 118(1):1-17. PubMed ID: 37212948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.
    Shallis RM; Podoltsev NA
    Curr Opin Hematol; 2021 Mar; 28(2):110-121. PubMed ID: 33394722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
    Medeiros BC; Chan SM; Daver NG; Jonas BA; Pollyea DA
    Am J Hematol; 2019 Jul; 94(7):803-811. PubMed ID: 30945331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life after transplant: are we becoming high maintenance in AML?
    Brunner AM; Fathi AT; Chen YB
    Bone Marrow Transplant; 2016 Nov; 51(11):1423-1430. PubMed ID: 27322850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
    Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.
    Martino M; Fedele R; Moscato T; Ronco F
    Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
    Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
    Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
    Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
    Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
    Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.